Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860
recruitingphase_1

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

NCT06704191
recruitingphase_2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

NCT06265285

Clinical Trials (3)

Showing 3 of 3 trials
NCT05969860Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Recruiting
NCT06704191Phase 1

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Recruiting
NCT06265285Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3